Quantcast

Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest.

Research paper by Oscar J OJ Cordero, Rubén R Varela-Calviño, Tania T López-González, Milica M Grujic, Zorica Z Juranic, Coral C Mouriño, Íñigo Í Hernández-Rodríguez, Marina M Rodríguez-López, Bruno Aspe BA de la Iglesia, José María JM Pego-Reigosa

Indexed on: 11 Jun '17Published on: 11 Jun '17Published in: Clinical Biochemistry



Abstract

Rheumatoid arthritis (RA) patients show low serum levels of the Ag dipeptidyl peptidase IV (DPP-IV/CD26), both soluble CD26 (sCD26) concentration and its DPP-IV activity. The aim of this study was to test if anti-DPP-IV/CD26 Abs (Anti-CD26) cleared sCD26.Serum Anti-CD26 and Total titers (as comparison) of isotypes IgA, IgM and IgG as well as sCD26 concentration and DPP-IV activity were measured in a cohort of RA patients undergoing different biological and non-biological therapies (n=105) and controls (n=50).Anti-CD26 levels were increased approximately two-fold for each isotype in RA, were not related to the sCD26 clearance, showed several correlations with disease activity parameters, were significantly higher in smokers and they were not ACPA. Anti-CD26 Igs showed high diagnostic power (82% sensitivity and 96% specificity) and their levels differed amongst the different groups of patients stratified by the type of therapy.As DPP-IV/CD26 is an associated to factors triggering RA in the lung and periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.

More like this: